Summit Therapeutics Inc (SMMT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months

In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Summit Therapeutics Inc’s stock clocked out at $9.12, down -3.70% from its previous closing price of $9.47. In other words, the price has decreased by -$3.70 from its previous closing price. On the day, 2.98 million shares were traded. SMMT stock price reached its highest trading level at $9.78 during the session, while it also had its lowest trading level at $9.06.

Ratios:

To gain a deeper understanding of SMMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.97 and its Current Ratio is at 6.97. In the meantime, Its Debt-to-Equity ratio is 2.48 whereas as Long-Term Debt/Eq ratio is at 2.39.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on May 07, 2024, initiated with a Buy rating and assigned the stock a target price of $7.

On March 26, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $8.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 27 ’24 when Zanganeh Mahkam bought 54,321 shares for $3.72 per share. The transaction valued at 201,874 led to the insider holds 24,923,800 shares of the business.

Zanganeh Mahkam bought 26,000 shares of SMMT for $96,720 on Mar 27 ’24. The Chief Executive Officer now owns 520,814 shares after completing the transaction at $3.72 per share. On Mar 26 ’24, another insider, Dhingra Ankur, who serves as the Chief Financial Officer of the company, bought 100,000 shares for $3.75 each. As a result, the insider paid 375,000 and bolstered with 354,958 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 6402057728 and an Enterprise Value of 6354895872.

Stock Price History:

The Beta on a monthly basis for SMMT is -0.96, which has changed by 3.3222747 over the last 52 weeks, in comparison to a change of 0.24125004 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $11.25, while it has fallen to a 52-week low of $1.52. The 50-Day Moving Average of the stock is 36.94%, while the 200-Day Moving Average is calculated to be 128.55%.

Shares Statistics:

It appears that SMMT traded 4.16M shares on average per day over the past three months and 2270990 shares per day over the past ten days. A total of 701.66M shares are outstanding, with a floating share count of 83.22M. Insiders hold about 88.14% of the company’s shares, while institutions hold 7.11% stake in the company. Shares short for SMMT as of 1719532800 were 20313904 with a Short Ratio of 4.88, compared to 1717113600 on 21261959. Therefore, it implies a Short% of Shares Outstanding of 20313904 and a Short% of Float of 24.379998.

Most Popular